Greg Dwyer
Senior Vice President, Business Development Orum Therapeutics
Greg Dwyer is Senior Vice President of Business Development at Orum Therapeutics, where he is responsible for corporate strategy, partnerships, and licensing activities supporting the company’s next-generation targeted protein degradation and antibody-based therapeutics. He brings extensive experience in biotech and pharmaceutical business development, with a track record of executing strategic collaborations and advancing innovative therapeutic platforms.
Seminars
Wednesday 9th September 2026
Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?
11:40 am
- Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
- Discussing initial proof-of-concept case studies for DACs
- Collaboration potential between antibody engineering and protein degradation companies
